Details of the Fund Raise
The capital raise is structured as a preferential allotment on a private placement basis to Rasmalai Limited, an entity incorporated in Cyprus. The company will issue up to 1,30,26,516 fully paid-up equity shares and 1,89,47,664 warrants, each carrying a right to subscribe to one equity share. Both instruments are priced at ₹985.17, which includes a premium of ₹975.17 per security.
For the warrants, 25% of the consideration is payable upfront, with the remaining 75% due at the time of exercise within a period of 15 to 18 months. The total cash consideration for this transaction is approximately ₹3,150 crore.
Strategic Rationale and Governance
- The investor will be classified as a public shareholder, representing a 24.87% stake post-issue
- Rasmalai Limited gains the right to nominate up to two non-executive directors to the Board
- Investor nominee rights extend to one seat each on the Audit and Nomination & Remuneration committees
- A special 'Promoter Incentive' allows Dr. Ajay Tyagi to receive a portion of investor profits if returns exceed 3x MOM
- Promoters will be subject to a three-year lock-in period from the closing date of the transaction
Business and Financial Overview
Yatharth Hospital operates as a leading super-specialty healthcare provider with a significant presence in the Delhi NCR region, including facilities in Noida, Greater Noida, and Faridabad, alongside a multi-specialty hospital in Madhya Pradesh. The company currently manages a total bed capacity of approximately 1,605 beds. Financially, the company has demonstrated robust growth, reporting TTM operating revenue of ₹1,334.11 crore and an annual net profit growth of 34.34%.
With a TTM P/E ratio of 52.22 compared to the industry average of 61.69, the company maintains a Durability Score of 60 on Trendlyne.
Industry Context and Capital Deployment
The Indian healthcare sector is witnessing a wave of consolidation and significant private equity interest as hospital chains seek to scale operations through brownfield expansions and strategic acquisitions. Yatharth's move to raise ₹3,150 crore aligns with this trend, providing the necessary capital to potentially fund inorganic growth opportunities or debt reduction. To facilitate the issuance, the Board has also approved increasing the authorized share capital from ₹115 crore to ₹150 crore.
The transaction remains subject to approval from the Competition Commission of India and the company's public shareholders.
